Thanks for highlighting our paper in your wonderful News & Views!

The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social. 🔗 www.stem.org.uk/resources/li...

DNGR-1 enables cDC1 to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens @natimmunol.nature.com @reisesousalab.bsky.social @crick.ac.uk www.nature.com/articles/s41... www.nature.com/articles/s41... preview by @magarianblander.bsky.social

Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure Thanks for sharing @drjonlim.bsky.social & congrats 🥳

#WeekendRead! #DendriticCellPower! @reisesousalab.bsky.social @drjonlim.bsky.social &co show @natimmunol.nature.com that cDC1s exploit DNGR1 to crosspresent #tumor #neoantigens derived from F-actin binding proteins protecting against tumorigenesis but favoring cancer immunoediting!

@drjonlim.bsky.social & @reisesousalab.bsky.social show cDC1s & DNGR1 favor "tethered" neoantigens from F-actin proteins, trapping them in necrotic debris for better cross-presentation! Calls for prioritizing these neoantigens for cancer vaccine design #Immunotherapy www.nature.com/articles/s41...

Absolutely delighted that our latest paper is out today @natimmunol.nature.com. It has taken five years to uncover a role for cross-presentation in shaping the immune visibility of tumour antigens. A labour of love led by @drjonlim.bsky.social and Oliver Schulz. Great start of 2026!

Very grateful to Prof. Blander & Dr. Jha for a thoughtful @natimmunol.nature.com 𝘕𝘦𝘸𝘴 & 𝘝𝘪𝘦𝘸𝘴 piece on our work 🙏 📄 A clear & critical perspective that places our findings in the broader context of dendritic cell biology, cross-presentation, and tumour immunoediting. @reisesousalab.bsky.social

Researchers at the Crick have uncovered how certain proteins that become exposed on dying tumour cells can be detected by the immune system, alerting it to the cancer’s presence and prompting an immune response. www.crick.ac.uk/news/2025-12...

My main PhD paper is finally out! 🎉 After ~5 years, it’s published today in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘐𝘮𝘮𝘶𝘯𝘰𝘭𝘰𝘨𝘺. @natimmunol.nature.com It all started with an unexpected observation 🔍: 👉 Mice lacking the dendritic cell receptor DNGR-1 developed tumours earlier ⏩ and more frequently 📈 than wild-type mice. 1/11 🧵

🎙️ Great to hear Samra @turajliclab.bsky.social and @manifest-cirrp.bsky.social featured on BBC Radio 5 Live 👇

🎉 50 years. 50,000 professionals. Advancing #oncology 🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO. Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer

🎙️ Enjoyed speaking with Salome Chkheidze, a medical student at Tbilisi State Medical University & journalist at Medscriptum, about precision oncology and the evolving opportunities (and challenges! of cell therapy in solid tumours. Many thanks for the interview feature 👇

Earlier this week, the CIM Connect event brought together cancer, immunology and cell–matrix researchers from across Manchester to spark new ideas and collaborations #ImmunoSky @mcrcellmatrix.bsky.social @cruk-mi.bsky.social Find out more about the event 👇 sites.manchester.ac.uk/lydia-becker...

🌍 This is one of the projects I’m most proud of since returning to Manchester 🇬🇧 🤝 🇺🇦. Huge thanks to Rachel, Harry, Jenny, Su, Prof Aziz, Prof Choudhury, Prof Cowan & many other #TeamManchester 🐝 colleagues at The Christie for making this happen. More to come - watch the space!

Wise and timely words from Rathmell & Shevde! Thanks for advocating for early career researchers - including clinical academics. If we truly care about the future of science and patient impact, investing in people has to come first - not as rhetoric, but as action 🙌 .

Hear more about RISE + why tackling safety/toxicity in advanced therapies is centre to our programme. We're humbled to hear from Elkie Mellor, who generously shared her lived experience. Voices like hers are a powerful reminder of why this work matters & will continue to motivate everything we do.

🚀 Excited to share the launch of our RISE consortium. RISE unites NHS, academic & industry partners to tackle immune-related toxicities in advanced cancer therapies, incl. CRS & neurotoxicity - centred around patient safety + quality of life. Funded by @ukri.org MRC Prosperity Partnership Award.

'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity' Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇

✨ #ESMOImmuno25 @turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London. The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.

Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London. If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.

If you're looking for careers support our 2026 mentoring scheme applications close on December 10 2025. Learn more here: www.immunology.org/careers/bsi-...

🩺 Fantastic opportunity for #YoungOncologists: ICF-ESMO programme for an 8-week observership. We've excellent opportunities here in Manchester & would be happy to support (✉️: [email protected]). @christieinstitute.bsky.social @myesmo.bsky.social 📥 For more info (due 25 Jan 2026) 👇

Excited about not one but 2 fantastic conferences in Manchester! So timely as cell therapies are on the standard care horizon!

⏰ Calling all melanoma enthusiasts! The abstract submission deadline for the inaugural “Lab to Life: Innovations in Melanoma Research Conference UK 2026” has been extended to 19 December 2025! Happening 12-13 March 2026 at The Midland Hotel, Manchester. Submit your abstract and register here:

🧬 CAR T treatments improve overall survival for patients with large B-cell lymphoma and progression-free survival for patients with multiple myeloma. Save this Review for your bibliography: ja.ma/49HHc34

🚀 Save the Date! We’re excited to launch our flagship TIL Summit in Manchester: "Unlocking TIL Therapy: A New Era for Melanoma Care in the UK" 🗓 11 March 2026 📍 The Midland Hotel, Manchester

End of an era! @marianapdc.bsky.social is one of the most talented scientists I have ever met; beyond that a super good friend 🙌. So honoured to have overlapped in the lab with you, and see you shine and rise to all the successes you so deserve. Thanks for all the wonderful times. All the best! 💫

The parents of a three-year-old boy born with a devastating, life-limiting genetic condition say they are now excited for his future after he received a revolutionary stem cell gene therapy treatment developed by researchers at the University of Manchester. www.bbc.co.uk/news/article...

Levy on international students’ tuition fees not in best interest of UK, says @duncanivison.bsky.social, president and VC of @manchester.ac.uk More from @theguardian.com bit.ly/4r1save #education #educationnews

Fantastic opportunity from @turajliclab.bsky.social! 🚀 The CanDy Lab is recruiting an Associate Scientist to drive cutting-edge cancer research across @cruk-mi.bsky.social and @crick.ac.uk. A rare chance to lead, grow, and shape high-impact science 👇 www.cruk.manchester.ac.uk/career/mi-25...

🚨 Save the Date! Next #ChristieFellows session: “Preparing a Grant Proposal for PhD or Research Projects” 🎤 Dr Jamie Weaver 🗓️ Tue 18 Nov 2025 | 12:30–13:30 📍 Seminar 4&5, Edu Centre Learn how to pitch your idea & navigate the grant process from an early-career clinical academic. #TeamManchester 🐝

We were proud to see #TeamManchester present at over 10 sessions & 20+ posters at #ESMO2025. Well done to everyone involved in representing the MCRC on this international stage & demonstrating the commitment of our researchers & clinicians!🐝 See you all in Spain for #ESMO26! 🇪🇸

So proud of my colleague Sacha Howell on this latest @nature.com publication reporting on the Breast Cancer-Anti-Progestin Prevention Study 1 (BC-APPS1) - many years in the making: www.nature.com/articles/s41... Press release from The University of Manchester: www.manchester.ac.uk/about/news/n...

#ESMO25: Positive efficacy results without safety concerns seen with NW-301V, a TCR-T therapy targeting KRAS G12V, in patients with KRAS G12V-mutant advanced #GICancer in a phase I #ClinicalTrial. #ESMODailyReporter🔗 https://ow.ly/jouK50XjATp Jon Lim, MRCP PhD

We joined forces across Europe to map, connect & accelerate the development of ATMPs — gene, cell and tissue-based therapies that could transform patient care. We make ATMP innovation faster, safer and more accessible for everyone. 👉 join4atmp.eu #JOIN4ATMP #ATMP #HorizonEurope #HealthInnovation

There’s still time to sign up for our Taster Session on Thursday 30 October to learn more about studying a #PhD in Cancer Sciences. ⏰ Learn about our application process 🧑‍ Hear from current students 🐝 Learn what it’s like to study in Manchester www.eventbrite.co.uk/e/cruk-mcrc-...

Our fourth and final day of #ESMO25! We listened to talks by Consultant & Fellow Alum Melissa Frizziero and Honorary Academic Consultant & Fellowships Specialty Lead for Medical Oncology @drjonlim.bsky.social! We also learned about the various professional development opportunities offered by ESMO 🎓

#ESMO25 Day 3 has been a huge success, with talks from a number of our Fellow Supervisors, including Dr Andrew Clamp presenting original research on the ICON8B trial. We also caught up with some of our current and previous fellows who have been presenting posters at the conference! 📊

Day 2 of #ESMO25 has been fantastic with many Christie speakers. ✨ Highlights include Prof. Corrine Faivre-Finn, Dr Mairead McNamara & Prof. Samra Turajlić. We were also delighted to see Gemma Jones, The Christie’s Lead Nurse for SACT, presenting on eProms in streamlining pre-treatment assessment.

On Day 1 of #ESMO25 we heard from Prof Fiona Thistlethwaite and Dr Matthew Krebs discussing developmental therapeutics. Over 35,000 delegates will be in attendance at the conference this year - we are delighted to be part of such a fantastic community 👏

🗞️ Check out my short #ESMODailyReporter editorial on early data from a first-in-human TCR-T therapy targeting KRAS G12V in advanced pancreatic & colorectal cancer, presented today by Dr Bai from Zhejiang University. #ESMO25 #CellTherapy #ESMOAmbassadors @myesmo.bsky.social

Friday we celebrated our new MRC Centre of Research Excellence in Exposome Immunology: a joint venture with Oxford that we call MOXIE (Manchester-Oxford Immunology of the Exposome). This challenging adventure is off to a great start. @exposomeimmunology.bsky.social

#ESMOAmbassadors: for the second year bringing you the life that is happening at #ESMO25. ✨ A heartfelt thank you to the #ESMOAmbassadors for their reporting on the latest in #CancerResearch & practice. Stay tuned! #ONEoncologycommunity

Delighted to be part of the #ESMOAmbassadors team at #ESMO25! 🌍 Let’s connect and discuss the latest news here in Berlin >>> and beyond! #ONEOncologyCommunity @myesmo.bsky.social

🌟 Tour de force proffered paper by Dr Charlotte Spencer, Histopathology SpR + recent PhD Fellow in @turajliclab.bsky.social @crick.ac.uk Huge congrats on the ESMO Merit Award 🎉 So well deserved — proud of you, my friend! 💫 #ESMO25 #TranslationalResearch #TRACERxRenal

💥 Is it prime time for adoptive cell therapy in solid tumours? 📚 Special Educational Session on the state-of-the-art and future of cell therapies - evolving fast from promise to practice. 👀 Watch this space… #ESMO25 #ESMOAmbassadors #CellTherapy #Immunotherapy

Strong representation from our Experimental Cancer Medicines Team (ECMT) at The Christie, led by Dr Matthew Krebs at #ESMO25. Mini-oral presentation re: global phase 1 data on divarasib (GDC-6036) - a next-gen KRAS G12C inhibitor with promising activity. #TeamManchester 🐝 @mcrcnews.bsky.social

Proud of my colleague Prof Fiona Thistlethwaite - Chair and Abstract Discussant at the Developmental Therapeutics track here at #ESMO25. #AICTteam #TeamManchester 🐝 @mcrcnews.bsky.social

Exciting days ahead in Berlin 🇩🇪 for #ESMO25! Some of our core team from @christieinstitute.bsky.social are here at the #ESMO25 Congress - come say hi 👋! Special shout-out to our #YoungOncologists colleagues - Always keen to connect, and discuss opportunities in Manchester. @mcrcnews.bsky.social